Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis
Pan Ma(Washington University in St. Louis), Kory J. Lavine(Washington University in St. Louis), Ruijun He(Washington University in St. Louis), Ana Villanueva(Washington University in St. Louis), Hannah Luehmann(Washington University in St. Louis), Kaushik Amancherla, Javid J. Moslehi(Cardiovascular Institute of the South), Antanisha Parks(JDSU (United States)), Andrea Bredemeyer(Washington University in St. Louis), Guoshuai Feng(Washington University in St. Louis), Deborah Sultan(Mallinckrodt (United States)), Chieh‐Yu Lin(Washington University in St. Louis), Jing Liu(Jisc), Juan Qin(Hainan University), Lulu Lai(Washington University in St. Louis), Matthias Mack(University Hospital Regensburg), Gyu Seong Heo(Mallinckrodt (United States)), Geetika Bajapa(Jisc), Junedh Amrute(Amgen (United States)), Yongjian Liu(Washington University in St. Louis), Jesús Jiménez(Washington University in St. Louis)
Cited by 146
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k